Literature DB >> 9069288

Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

W C Su1, M Kitagawa, N Xue, B Xie, S Garofalo, J Cho, C Deng, W A Horton, X Y Fu.   

Abstract

The achondroplasia class of chondrodysplasias comprises the most common genetic forms of dwarfism in humans and includes achondroplasia, hypochondroplasia and thanatophoric dysplasia types I and II (TDI and TDII), which are caused by different mutations in a fibroblast growth-factor receptor FGFR3 (ref. 1). The molecular mechanism and the mediators of these FGFR3-related growth abnormalities are not known. Here we show that mutant TDII FGFR3 has a constitutive tyrosine kinase activity which can specifically activate the transcription factor Stat1 (for signal transducer and activator of transcription). Furthermore, expression of TDII FGFR3 induced nuclear translocation of Stat1, expression of the cell-cycle inhibitor p21(WAF1/CIP1), and growth arrest of the cell. Thus, TDII FGFR3 may use Stat1 as a mediator of growth retardation in bone development. Consistent with this, Stat1 activation and increased p21(WAF1/CIP1) expression was found in the cartilage cells from the TDII fetus, but not in those from the normal fetus. Thus, abnormal STAT activation and p21(WAF1/CIP1) expression by the TDII mutant receptor may be responsible for this FGFR3-related bone disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9069288     DOI: 10.1038/386288a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  72 in total

1.  A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1.

Authors:  R L Haspel; J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 2.  Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism.

Authors:  William A Horton; Gregory P Lunstrum
Journal:  Rev Endocr Metab Disord       Date:  2002-12       Impact factor: 6.514

3.  High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1.

Authors:  A Sewing; B Wiseman; A C Lloyd; H Land
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma.

Authors:  D Sampath; M Castro; D C Look; M J Holtzman
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

5.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

6.  Protein kinase PKR is required for platelet-derived growth factor signaling of c-fos gene expression via Erks and Stat3.

Authors:  A Deb; M Zamanian-Daryoush; Z Xu; S Kadereit; B R Williams
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

7.  Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis.

Authors:  Y E Chin; M Kitagawa; K Kuida; R A Flavell; X Y Fu
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

8.  Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway.

Authors:  S Murakami; M Kan; W L McKeehan; B de Crombrugghe
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

9.  Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation.

Authors:  Sunhwa Kim; Takako Koga; Miho Isobe; Britt E Kern; Taeko Yokochi; Y Eugene Chin; Gerard Karsenty; Tadatsugu Taniguchi; Hiroshi Takayanagi
Journal:  Genes Dev       Date:  2003-08-15       Impact factor: 11.361

10.  Signal transducers and activators of transcription mediate fibroblast growth factor-induced vascular endothelial morphogenesis.

Authors:  Xinhai Yang; Dianhua Qiao; Kristy Meyer; Andreas Friedl
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.